Quick Comparison
| AEDG Peptide | Epithalon | |
|---|---|---|
| Half-Life | 1-2 hours | 2-4 hours |
| Typical Dosage | Oral/sublingual: 10-20 mg once daily. Injectable: 1-10 mg subcutaneous once daily. Typical course: 10-20 days, repeated every 3-6 months. Same protocols as Epithalon. | Standard: 5-10 mg subcutaneous once daily for 10-20 days. Cycled two or three times per year. Some protocols use 10 days on, followed by a 4-6 month break before repeating. |
| Administration | Subcutaneous injection, oral, or sublingual | Subcutaneous or intravenous injection |
| Research Papers | 8 papers | 4 papers |
| Categories |
Mechanism of Action
AEDG Peptide
AEDG peptide (Ala-Glu-Asp-Gly) is the minimal active sequence of Epithalon and represents the core tetrapeptide responsible for its reported biological effects. According to the Khavinson peptide bioregulator theory, this short sequence has tissue-specific gene-regulatory activity, particularly targeting pineal gland cells and somatic cells capable of telomerase expression.
The primary reported mechanism is activation of telomerase, the ribonucleoprotein enzyme that maintains telomere length. AEDG is proposed to interact with regulatory elements in the hTERT gene promoter (encoding the catalytic subunit of telomerase), enhancing its transcription in somatic cells where hTERT is normally silenced or minimally expressed. Reactivation of telomerase allows cells to add TTAGGG telomeric repeats to chromosome ends, counteracting the progressive telomere shortening that occurs with each cell division and ultimately triggers replicative senescence. Cell culture studies from the Khavinson laboratory have reported that AEDG treatment extends the replicative lifespan of human fibroblasts and increases telomerase activity in peripheral blood mononuclear cells.
The second major reported mechanism involves regulation of pineal gland function. The pineal gland produces melatonin — the circadian rhythm hormone and potent antioxidant — and its function declines markedly with age (pineal calcification and reduced melatonin output). AEDG is proposed to modulate gene expression in pinealocytes, restoring melatonin synthesis toward more youthful levels. This would have downstream effects on circadian rhythm regulation, sleep quality, antioxidant defense, and immune function — all of which are modulated by melatonin. Additional reported effects include upregulation of antioxidant enzyme expression (SOD, catalase) and modulation of cell cycle regulatory genes. As with other Khavinson peptide bioregulators, the research base is predominantly from Russian institutions, and the proposed direct DNA-binding mechanism awaits independent validation.
Epithalon
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on epithalamin, a peptide extract from the pineal gland first studied by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary reported mechanism is the activation of telomerase — the ribonucleoprotein enzyme complex responsible for maintaining telomere length at chromosome ends.
Telomeres are repetitive nucleotide sequences (TTAGGG in humans) that cap and protect chromosome ends from degradation, fusion, and recognition as DNA damage. With each cell division, the DNA replication machinery cannot fully copy the very end of the lagging strand (the 'end replication problem'), resulting in progressive telomere shortening. When telomeres reach a critical length, cells enter replicative senescence (permanent growth arrest) or apoptosis — a fundamental mechanism of cellular aging. Telomerase, composed of the catalytic subunit hTERT (human telomerase reverse transcriptase) and the RNA template component hTR/TERC, can add TTAGGG repeats back to chromosome ends, counteracting this shortening.
Epithalon reportedly activates the expression of the hTERT gene, increasing telomerase activity in somatic cells. In cell culture studies, epithalon treatment was associated with increased telomere length and extended replicative lifespan in human fibroblasts and retinal pigment epithelial cells. The peptide also reportedly stimulates melatonin production by the pineal gland, potentially through gene-regulatory effects on pineal cells. Melatonin itself is a potent antioxidant and circadian regulator, and its decline with age correlates with numerous age-related changes. Additional reported effects include normalization of T-cell function, modulation of neuroendocrine signaling, and improved antioxidant enzyme expression. It should be noted that the majority of published research comes from Russian institutions, and large-scale, peer-reviewed Western clinical trials are lacking.
Risks & Safety
AEDG Peptide
Common
injection site irritation, mild drowsiness.
Serious
telomerase activation may promote pre-cancerous cells, limited Western safety data.
Rare
allergic reactions.
Epithalon
Common
irritation at the injection site, mild headache, brief drowsiness.
Serious
activating telomerase could promote pre-cancerous or cancerous cells; most research comes from Russian institutions with limited Western clinical data.
Rare
allergic reactions.
Full Profiles
AEDG Peptide →
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
Epithalon →
A lab-made peptide based on a natural compound from the pineal gland (a small gland in your brain). It's studied for its ability to activate telomerase, the enzyme that keeps the protective caps on the ends of your chromosomes from shortening. Since those caps naturally shorten as cells age, this peptide is one of the most talked-about in anti-aging research. Originally developed in Russia.